Is Canopy Growth (TSX:WEED) Stock a Buy Right Now?

After underperforming, cannabis stocks like Canopy Growth may finally be worth looking at.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Cannabis stocks have been part of an extended bear market. Shares of most pot companies have been pummelled in the last 15 months. Marijuana heavyweight Canopy Growth (TSX:WEED)(NYSE:CGC) has lost over 70% in market value since September 2018.

Several pot stocks were trading at sky-high valuations after Canada legalized the use of recreational cannabis. While investors were worried about soaring valuations, this industry was severely impacted due to a range of structural issues.

As cannabis is a highly regulated industry, retail licenses are not given out easily. The slow rollout of retail stores in major Canadian provinces has resulted in lower than expected demand, driving inventory levels higher and profit margins lower for several pot stocks.

The COVID-19 pandemic has further dented the key financial metrics of these organizations. Many cannabis companies are running out of cash, and the current uncertain environment will make it difficult to raise debt or equity capital. So, are stocks like Canopy Growth an attractive buy right now after falling 70% from all-time highs?

Canopy Growth streamlines operations

On April 16, Canopy Growth announced operational changes aimed at optimizing production and align supply with demand. It plans to exit operations in South Africa and will transfer ownership of its African operations to a local business.

The company will also shut down its indoor facility in Saskatchewan to better align production in line with domestic demand. In Latin America, it will cease operations at its cultivation facility in Colombia and move to an asset-light model. Canopy Growth will also cease operations in its New York facility due to “an abundance” of hemp production in 2019.

In March 2020, Canopy Growth also announced 500 job cuts. These restructuring efforts are aimed at lowering the company’s cost structure and reducing cash burn.

Newly appointed CEO wants to optimize operations

CEO David Klein took over the reins as Canopy Growth’s CEO earlier this year. Klein was previously the CFO of Constellation Brands, a company that pumped in $4 billion into Canopy for a 38% stake back in 2018.

As a former CFO, Klein has trained his guns on optimizing the company’s cost structure. Canopy Growth will now primarily focus on Canadian operations that account for the majority of sales.

In the last three quarters, international sales accounted for 14.6% of total revenue. So, the above-mentioned exits will not have a significant impact on Canopy’s top-line.

What’s next for Canopy Growth investors?

Despite the 70% decline in valuation, however, Canopy Growth is still trading at a market cap of $7.65 billion, making it one of the largest players in the cannabis space. It is backed by Constellation Brands that continues to allocate resources to the cannabis giant.

The COVID-19 is expected to be a temporary headwind, and demand should pick up in the second half of 2020. The cannabis market is still in its nascent stage and is expected to grow at a fast clip in the upcoming decade.

The market opportunity in the edibles space, increase in retail stores, leadership position and expanding addressable market make Canopy Growth a solid pick for long-term investors.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »